Th17 cells are a subset of T cells that produce IL-17A, IL-17F, IL-6, and TNF ([@bib9]; [@bib21]; [@bib35]; [@bib18]; [@bib39]; [@bib3]; [@bib33]). They are involved primarily in mediating inflammatory diseases and immune defense against extracellular bacteria. Th17 cells can be generated from naive precursors in the presence of TGF-β and IL-6 or IL-21 ([@bib3]), which can be further augmented by TNF or IL-1β (inflammatory cytokines that inhibit Th1 and Th2 cell differentiation; [@bib33]; [@bib8]). Developments of Th1, Th2, and regulatory T cells (T reg cells) are specified by transcription factors such as Tbet, GATA3, and Foxp3, respectively, whereas that of Th17 cells appears to depend on the retinoid-related orphan receptor (ROR) γT, RORα, and signal transducer and activator of transcription (STAT3; [@bib18]; [@bib41], [@bib42]).

RORγT and its isoform RORγ are encoded by a single gene called *Rorg* (also known as *Rorc*). Both isoforms use the last 9 exons (exons 3--11) of the *Rorg* gene, but the other exons used by them are different. As a consequence, the RORγT mRNA differs from that of RORγ in the first 100 nt, which translate into distinct N-terminal aa sequences ([@bib14]; [@bib36]). Nonetheless, both isoforms have the same DNA-binding domain and ligand-binding domain. In fact, RORγ contains all but three N-terminal aa of RORγT, which has a total of 495 aa (RORγ has 516 aa). The two isoforms differ in their expression patterns. RORγT is preferentially expressed in the thymus and differentiated Th17 cells, whereas RORγ is expressed in a variety of organ systems, including muscle, kidney, and liver, although its expression in Th17 cells has not been examined. Whether the two isoforms are generated as a result of alternative usage of different promoters or alternative splicing of a common pre-mRNA is not clear. RORγT is considered to be a lineage-specific marker of Th17 cells. It is induced during Th17 differentiation, and can directly activate genes encoding IL-17A and IL-17F. RORγT-deficient T cells are significantly compromised in their Th17 differentiation program ([@bib18]). Whether and to what degree the RORγ isoform plays a role in Th17 differentiation is unknown.

The mammalian Rel/NF-κB family consists of five members: c-Rel, p65 (or RelA), RelB, NF-κB1 (p50/p105), and NF-κB2 (p52/p100; [@bib2]; [@bib1]). Unlike other members that are constitutively expressed in multiple cell types, c-Rel is expressed primarily in lymphoid tissues by lymphoid and myeloid cells ([@bib4]; [@bib31]; [@bib38]; [@bib16]; [@bib11]). c-Rel--deficient mice do not suffer from developmental problems or infectious diseases, and c-Rel--deficient T cells are competent in survival but are significantly compromised in TCR-induced gene expression ([@bib19]; [@bib34]; [@bib15]; [@bib5]). We report here that c-Rel and p65 play a crucial role in activating the *Rorg* gene that is required for initiating Th17 differentiation.

RESULTS
=======

T cells deficient in c-Rel or RelA/p65 are significantly compromised in Th17 differentiation and Th17 responses
---------------------------------------------------------------------------------------------------------------

To determine the potential roles of c-Rel in Th17 immunity, we compared WT and c-Rel--deficient T cells for their Th17 responses. We found that CD4^+^ T cells freshly isolated from c-Rel--deficient mice produced significantly less IL-17A mRNA and protein upon activation with anti-CD3 and anti-CD28 ([Fig. 1, A and B](#fig1){ref-type="fig"}). This was associated with reduced levels of both RORγ and RORγT mRNAs as compared with WT cells ([Fig. S1 A](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp1}). Consistent with this result, we found that c-Rel deficiency caused a 46% reduction in the frequency of Th17 cells in the lung (1.1 ± 0.1% in WT as compared with 0.6 ± 0.05% in c-Rel KO mice), and 44% reduction in the Peyer's patches (1.6 ± 0.1% in WT as compared with 0.9 ± 0.07% in c-Rel KO mice; P \< 0.03 for both organs). Importantly, when purified naive CD4^+^ T cells were cultured under Th17 cell--inducing conditions, IL-17A expression was significantly reduced in the c-Rel--deficient group, leading to ∼50% reduction in Th17 cell frequencies ([Fig. 1, C and D](#fig1){ref-type="fig"}); this reduction was more dramatic (up to 80%) if anti--IL-2 was added to the culture twice and phorbol myristate acetate (PMA) and ionomycin were not used to stimulate the cells (Fig. S1 B). c-Rel deficiency not only reduced the Th17 cell frequency, but also decreased the levels of IL-17 in differentiated Th17 cells by ∼50% (Fig. S1 C). Because IL-2 represses Th17 differentiation through Stat5 ([@bib22]), the percentage of Th17 cells was higher in the presence of anti--IL-2.

![**T cells deficient in c-Rel or p65 are significantly compromised in their IL-17 gene expression and Th17 differentiation.** (A and B) CD4^+^ T cells were isolated from 6-wk-old WT and *Rel^−/−^* mice (*n* = 5), and stimulated with anti-CD3 and anti-CD28 in the presence of anti--IL-2 and anti--IFN-γ for 6 h (A), or 48 h (B). Total RNA was extracted, and IL-17 mRNA levels were determined by real-time RT-PCR (A). The cytokine concentrations in the culture supernatants were determined by ELISA (B). (C and D) Purified CD4^+^ naive splenic T cells from WT and *Rel^−/−^* mice (*n* = 5) were cultured under Th17 cell--inducing conditions, as described in Materials and methods, with or without anti--IL-2 for 3 d. Cells were then restimulated with PMA and ionomycin in the presence of GolgiStop for 4 h, stained intracellularly with antibodies to IL-17A, and analyzed by flow cytometry. In C, IL-17A expression level of cells cultured with anti--IL-2 was plotted against CD4. In D, the percentages of IL-17A-expressing cells (as shown in C) from each group were compared. Error bars indicate the SDs of the means. (E) Purified CD4^+^ naive splenic T cells from WT and *Rel^−/−^* mice (*n* = 3) were incubated with 5 µM of CFSE for 10 min. After washing, cells were cultured under the Th17 cell--inducing condition, as described in Materials and methods. 3 d later, cells were restimulated with PMA and ionomycin in the presence of GolgiStop for 4 h, stained intracellularly with antibodies to IL-17A, and analyzed by flow cytometry. Each numerical figure in the graph represents the percentage of cells with the same number of divisions in the gated area. (F) *p65^−/−^* and *p65^+/+^* chimeric mice were generated by adoptively transferring *p65^−/−^* and *p65^+/+^* fetal liver cells, respectively, into irradiated B6 recipients as previously described ([@bib26]). 6 wk later, mice were sacrificed and CD4^+^ naive splenic T cells isolated. Cells were cultured under Th17 cell--inducing medium for 3 d, as described in Materials and methods. They were then restimulated and tested as described in C. The number in each panel represents the percentage of gated IL-17A--producing cells in total CD4^+^ cells. Results are representative of three independent experiments. \*, P \< 0.01.](JEM_20110462_GS_Fig1){#fig1}

In addition to IL-6, IL-1 and IL-23 can also drive Th17 cell differentiation. The effect of c-Rel deficiency on IL-1-- and IL-23--induced Th17 cell differentiation was even more dramatic, reducing the Th17 cell frequency by ∼80% (Fig. S1 D). It has been reported that IL-17^+^IFN-γ^+^ cells can be induced by IL-6, IL-23, and IL-1. Because c-Rel also regulates IFN-γ expression, we next examined whether c-Rel deficiency affected the generation of IL-17^+^IFN-γ^+^ cells. We found that the frequency of IL-17 and IFN-γ double-positive cells was markedly reduced in c-Rel--deficient cultures (Fig. S1 E). *Rel^−/−^* T cells may have reduced proliferation ([@bib15]). To determine whether c-Rel regulates Th17 cell differentiation independent of its effect on cell proliferation, we repeated the Th17 differentiation experiment using naive CD4^+^ T cells labeled with CFSE, which allows direct tracking of cell divisions by flow cytometry. As expected, *Rel^−/−^* T cells have reduced proliferation ([Fig. S2 A](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp2}). Th17 differentiation peaked after the fourth cell division in both WT and *Rel^−/−^* groups ([Fig. 1 E](#fig1){ref-type="fig"}). Importantly, the percentage of Th17 cells generated was substantially reduced in the *Rel^−/−^* group even when cells that had undergone the same number of cell divisions were compared. Although a small population of cells that had undergone no division or less than two divisions also produced low levels of IL-17 (as indicated by a weak IL-17 signal; [Fig. 1 E](#fig1){ref-type="fig"}), they were likely uncommitted Th0-type cells, not Th17 cells, and were less affected by the c-Rel deficiency. T cell death as determined by flow cytometry was not significantly affected by the c-Rel deficiency. *Rel^−/−^* mice used in this study were \>7 wk old, and did not have significantly reduced splenic CD4^+^ T cells as compared with WT mice. There were no significant differences in the expression of CD44 and CCR6 between WT and *Rel^−/−^* T cells (Fig. S2 B). Upon activation, a low percentage of *Rel^−/−^* T cells produced IFN-γ, but few WT or *Rel^−/−^* T cells produced IL-22 (Fig. S2 C).

Because significant numbers of Th17 cells were generated in the absence of c-Rel, we asked whether other members of the Rel/NF-κB family played a role in Th17 differentiation. We found that *p65^−/−^* CD4^+^ T cells had a greater defect in Th17 differentiation than *Rel^−/−^* T cells ([Fig. 1 F](#fig1){ref-type="fig"}). Up to 70% reduction in Th17 cell frequencies was observed in the *p65^−/−^* group as compared with the WT group. Using CFSE-labeled *p65^−/−^* cells, we found that p65 deficiency significantly blocked Th17 differentiation, even when cells that had undergone same numbers of divisions were compared ([Fig. S3 A](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp3}). Specifically, the percentages of Th17 cells were reduced from 32.2% in WT to 12.5% in p65 cultures after four divisions, and from 19.9% in WT to 11.5% in p65 cultures after three divisions (P \< 0.01). To ensure that the culture condition we used was effective in driving Th17 differentiation, unlabeled cells were also cultured in a nondifferentiation medium. Few IL-17--producing cells were generated in the latter medium (Fig. S3 B). Because p65 deficiency causes embryonic lethality, fetal liver transfer was performed to generate the p65-deficient cells, as previously described ([@bib26]). In contrast to c-Rel and p65, p50 and RelB were dispensable because T cells deficient in them exhibited no defects in Th17 cell differentiation (unpublished data). These results indicate that c-Rel and p65 play critical roles in Th17 responses, and deficiency in one may only be partially compensated by the other.

RORγ and RORγT expression is markedly reduced in c-Rel--deficient T cells, and their reconstitution rescues the Th17 defect
---------------------------------------------------------------------------------------------------------------------------

c-Rel--deficient T cells have a defect in their Th1 but not Th2 responses ([@bib15]). To establish the degree to which Th17 response was affected in these cells, we examined the expression of seven Th17-related genes at different stages of Th17 differentiation. We found that c-Rel deficiency significantly reduced the expression of RORγT, RORγ, RORα4, IL-6, IL-17A, and IL-21, but not Stat3 mRNAs ([Fig. 2 A](#fig2){ref-type="fig"} and [Fig. S4 A](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp4}). As expected, RORγT and RORγ protein levels were also markedly reduced in c-Rel--deficient T cells (Fig. S4 B). Because RORγT plays a key role in Th17 differentiation, we next examined whether RORγT or RORγ reconstitution in c-Rel--deficient cells could rescue the Th17 defect. After infection of T cells with a retrovirus that carried either RORγT or RORγ cDNA, significant increases in the number of Th17 cells were observed in both WT and c-Rel--deficient groups. This was true for T cells cultured under either Th0 ([Fig. 2 B](#fig2){ref-type="fig"}) or Th17 (Fig. S4 C) cell--inducing conditions. RORγT and RORγ were both effective in driving IL-17 expression, and coexpressing them together did not appear to generate any synergistic effect (Fig. S4 C; unpublished data). The difference in the frequency of IL-17A producers between WT and c-Rel--deficient cells ([Fig. 2 B](#fig2){ref-type="fig"}) was most likely caused by the increased IL-2 production in WT cultures ([@bib15]). Importantly, similar to the reported effect of RORγT, RORγ also drove the expression of other Th17 signature molecules such as IL-17F, CCR6, IL-22, and IL-23R ([Fig. 2, C and D](#fig2){ref-type="fig"}). Because T cell proliferation may affect Th17 cell development, we also examined whether enforced expression of RORγ or RORγT had any effect on the proliferation of *Rel^−/−^* cells. Our data showed that enforced expression of neither RORγ nor RORγT rescued the proliferation defect of *Rel^−/−^* T cells ([Fig. S5, A and B](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp5}).

![**RORγ and RORγT expression is significantly reduced in c-Rel--deficient T cells, and RORγ reconstitution rescues the Th17 defect.** (A) Purified naive CD4^+^ splenic T cells from 6-wk-old WT (*n* = 5) and *Rel*^−/−^ (*n* = 5) mice were cultured under Th17 differentiation condition as described in Materials and methods. Cells were collected at different time points as indicated, and total RNA was extracted. The mRNA levels of the indicated genes were determined by real-time RT-PCR and normalized to GAPDH. Error bars indicate the SDs of the means, which are visible only if they are bigger than the diameters of the symbols. (B) Purified splenic CD4^+^ T cells from WT (*n* = 5) and *Rel*^−/−^ mice (*n* = 5) were cultured under Th0-inducing conditions in the presence of anti--IL-4 and anti--IFN-γ for 24 h. Cells were then infected with recombinant retroviruses that carry EGFP (Vector as a control), RORγ-EGFP (RORγ), or RORγt-EGFP (RORγt) cDNA as described in Materials and methods. 4 d later, cells were restimulated with PMA and ionomycin and stained intracellularly with anti--IL-17A, and analyzed by flow cytometry. Data shown are for gated EGFP^+^ cells. Results are representative of two independent experiments. (C and D) Splenic CD4^+^ T cells were isolated from 6-wk-old WT (C) and *Rel^−/−^* (D) mice (*n* = 3), and infected with recombinant retroviruses that carry EGFP (vector control), RORγ-EGFP, or RORγT-EGFP cDNA, as described in B. 4 d later, EGFP^+^ cells were sorted, total RNA was extracted, and mRNA levels of the indicated genes were determined by real-time RT-PCR. Data shown are fold increases over vector-treated groups, and are means and SD of triplicate cultures. Results are representative of two independent experiments.](JEM_20110462_GS_Fig2){#fig2}

Similar to RORγT, RORγ is preferentially expressed in Th17 cells and is effective in driving Th17 differentiation
-----------------------------------------------------------------------------------------------------------------

Although it is well recognized that RORγT plays a key role in specifying Th17 differentiation, whether RORγ plays a similar role is unknown. During in vitro Th cell differentiation, Th17-like cells expressed the highest levels of RORγ, in addition to RORγT ([Fig. 3, A and B](#fig3){ref-type="fig"}), although RORγT was clearly more abundant than RORγ ([Fig. 3 C](#fig3){ref-type="fig"}). T reg cell--like cells also expressed RORγ and RORγT during the differentiation stage, although their levels were much lower. Low levels of RORγ, but not RORγT, were also detected in Th1- and Th2-like cells at this stage ([Fig. 3, A and B](#fig3){ref-type="fig"}). RORγ is known to be expressed in nonhematopoietic cells, with the highest expression levels detected in the kidney and liver. We therefore compared RORγ mRNA copy numbers in Th17 cells to those in the kidney and liver. We found that the RORγ mRNA in Th17 cells was approximately one-half and one-fourth of those in the liver and kidney, respectively ([Fig. 3 D](#fig3){ref-type="fig"}). These results indicate that RORγ, in addition to RORγT, may be involved in specifying Th17 differentiation. Indeed, RORγ was at least as effective as RORγT in activating the *Il17a* promoter ([Fig. 3, E and F](#fig3){ref-type="fig"}). And enforced expression of RORγ through retroviral gene transfer induced Th17 differentiation even under Th0-, Th2-, and T reg cell--polarizing conditions ([Fig. 3 G](#fig3){ref-type="fig"}). Enforced expression of RORγ also decreased IL-4 levels under Th2-polarizing condition, but not IFN-γ under Th1-polarizing condition or Foxp3 under T reg cell--polarizing condition ([Fig. S6 A](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp6}). Because it has been reported that RORγT activates the *Il17a* gene by binding to its conserved noncoding sequence (CNS) 2 region ([@bib42]), we performed chromatin immunoprecipitation (ChIP) analysis of this region for RORγ binding. Because the currently available anti-RORγ antibodies do not distinguish RORγ from RORγT, we infected CD4^+^ T cells with a retrovirus that encodes Flag-tagged RORγ, or a combination of equal amounts of RORγ-Flag and RORγT retroviruses. RORγ-Flag binding to the *Il17a* gene was detected in both conditions, although RORγT retrovirus infection reduced the RORγ-Flag binding suggesting competition between RORγ and RORγT (Fig. S6 B). Collectively, these data indicate that in addition to RORγT, RORγ may also be involved in driving Th17 differentiation.

![**RORγT and RORγ activate the *Il17* promoter and drive Th17 differentiation.** (A and B) Purified CD4^+^ T cells were cultured under conditions that induce Th0, Th1, Th2, Th17, and T reg cells as described in Materials and methods. 3 d later, cells were harvested and restimulated with PMA and ionomycin for an additional 3 h. The RORγT (A) and RORγ (B) mRNA levels were determined by real-time RT-PCR, and are presented as fold increases over that of the Th0 cells. Data shown are representative of two independent experiments. (C and D) Total RNA was extracted from naive CD4^+^ T cells (*Naive*), Th17 cells, thymocytes, peritoneal macrophages, kidney, and liver of B6 mice as indicated. The mRNA copy numbers of RORγ and RORγT were determined by real-time RT-PCR using the respective cDNAs as standards. (E and F) EL4 T cells were transiently transfected with luciferase constructs of the murine *Il17a* promoter (*Il17* Pro) or *Il17a* promoter linked to its CNS2 (*Il17* Pro + CNS2), together with an expression vector for full-length RORγT (C) or RORγ (D), or the empty vector as indicated. After 24 h, cells were treated with PMA and ionomycin for 4 h, and the luciferase activities measured. The promoter activity is presented as fold increase over cells transfected with the empty vector. To normalize the transfection efficiency across samples, the *Renilla* luciferase expression vector pRLTK was used as an internal control. Data are representative of two independent experiments. \*, P \< 0.01. (G) Purified CD4^+^ T cells were cultured under conditions that induce Th0, Th1, Th2, Th17, and T reg cells for 24 h, and then infected with retroviruses that encode EGFP (Vector) or RORγ and EGFP (RORγ) as described in Materials and methods. 4 d later, cells were restimulated with PMA and ionomycin in the presence of GolgiStop for 4 h, stained intracellularly with antibodies to IL-17A, and analyzed by flow cytometry. Data shown are for gated EGFP^+^ cells. The experiment was repeated twice with similar results.](JEM_20110462_LW_Fig3){#fig3}

RORγ and RORγT expression is controlled by two different promoters in Th17 cells
--------------------------------------------------------------------------------

The *Rorg* gene encodes both RORγ and RORγT that are different in their N-terminal sequences. Whether this is a result of differential usage of different promoters or differential splicing of the same pre-mRNA in Th17 cells is not clear. To address this issue, we undertook three complementary approaches. First, we performed 5′-RACE (rapid amplification of cDNA ends) using a cap-dependent RACE kit to identify the transcription start sites (TSS) of Rorg mRNA in newly differentiated Th17 cells. This led to the discovery of two different types of ROR mRNAs in Th17 cells, with unique 5′ capped ends corresponding to two predicted TSS of the *Rorg* gene ([Fig. 4, A and B](#fig4){ref-type="fig"}; Fig. S7; and Fig. S8). The *Rorgt* TSS we identified in Th17 cells is identical to that reported for thymocytes ([@bib40]), whereas the *Rorg* TSS we identified is the same as the one reported for hepatocytes ([@bib25]).

![**Identification of two *Rorg* promoters that control RORγ and RORγT expression in Th17 cells.** (A) The translation start sites for RORγ and RORγT promoters are indicated by triangles and their TSS marked with arrows. Only 3 of the 11 *Rorg* exons are shown. (B) Purified CD4^+^ T cells from 6-wk-old WT mice (*n* = 3) were cultured under Th17 differentiation condition for 17 h, as described in Materials and methods. Total RNA was extracted and treated with RNase-free DNase I. 5′-RACE was performed and the PCR products of the 5′ ends of RORγ and RORγt mRNA were visualized by agarose gel electrophoresis (which were then cloned and sequenced). (C) Purified CD4^+^ T cells from 6-wk-old WT mice (*n* = 3) were cultured under Th17 differentiation conditions, as described in Materials and methods. At the indicated times, cells were fixed, and ChIP was performed using antibodies to RNA polymerase II (PolII) or control IgG. (D) Purified naive CD4^+^ T cells from WT (*n* = 3) and *Rel^−/−^* mice (*n* = 3) were cultured under Th17 differentiation conditions, as described in Materials and methods. At the indicated times, cells were fixed, and ChIP was performed using antibodies to PolII. Error bars indicate the SEM. Data are representative of two independent experiments (\*, P \< 0.05).](JEM_20110462_GS_Fig4){#fig4}

Second, we asked whether the RNA polymerase II (PolII) was able to bind to the two putative *Rorg* promoters during Th17 differentiation by ChIP. We found that although they followed different kinetics, both *Rorg* and *Rorgt* promoters associated with PolII during Th17 differentiation, especially at a later stage ([Fig. 4 C](#fig4){ref-type="fig"}). As expected, the binding was significantly reduced in *Rel^−/−^* cells ([Fig. 4 D](#fig4){ref-type="fig"}). Each *Rorg* promoter contains several CNS regions (Fig. S7 and Fig. S8). A TATA box and putative binding sites for several transcription factors including SP1, NFAT, AP-1, and GATA3, as well as Rel/NF-κB, are present within, or close to, the CNS-1 region. Collectively, these results indicate that differential promoter usage is likely responsible for the production of the two isoforms of the *Rorg* proteins.

Third, we tested whether the putative *Rorg* promoter (nt −771 to +98; [Fig. S7](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp7}) and the *Rorgt* promoter (nt −400 to +151; [Fig. S8](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp8}) had any detectable promoter activity in the Th17-like EL-4 cells. We found that although the *Rorgt* promoter was less sensitive than the *Rorg* promoter to stimulation, both promoter constructs could drive luciferase expression ([Fig. 5 A](#fig5){ref-type="fig"}). In fact, even in the absence of stimulation, the *Rorgt* promoter had a detectable basal activity. This is reminiscent of the study by Xi et al. that *Rorgt* promoter is constitutively active in a thymocyte cell line ([@bib40]).

![***Rorg* and *Il17* promoters.** (A) EL4 T cells were transfected with empty pGL3 vector, *Rorg*, or *Rorgt* promoter constructs with or without a c-Rel expression plasmid as indicated. After 24 h, cells were treated with or without 50 ng/ml PMA and 1 µM ionomycin (I) for 5 h and the luciferase activities of whole-cell lysates were analyzed as described in Materials and methods using a dual-luciferase reporter assay system. (B) EL4 cells were transiently transfected with murine *Il17a* core promoter or *Il17a* core promoter-CNS2 luciferase construct together with an expression vector for full-length RORγT, RORγ, p50, p52, c-Rel, p65, p100, or RelB, or the empty vector as indicated. After 24 h, cells were treated with PMA and ionomycin for 4 h, and the luciferase activities measured. The promoter activity is presented as fold increase over cells transfected with empty vector. To normalize the transfection efficiency across samples, the *Renilla* luciferase expression vector pRLTK was included as an internal control. Data are representative of two independent experiments. \*, P \< 0.01.](JEM_20110462_LW_Fig5){#fig5}

Rel activates both *Rorg* and *Rorgt* promoters, but not those of *Rora4* and *Il17a*
-------------------------------------------------------------------------------------

Although c-Rel--deficient T cells have a defect in IL-17A and RORα expression, c-Rel does not appear to regulate their promoter activities. Thus, the *Il17a* promoter construct containing its CNS2 enhancer was readily activated by RORγ and RORγT, but not by any members of the NF-κB family ([Fig. 5 B](#fig5){ref-type="fig"}). Similarly, c-Rel did not activate the promoter construct of *Rora4* (our unpublished data). These results indicate that the c-Rel effect on Th17 cells may be gene-specific.

To test the theory that Rel proteins control *Rorg* gene expression, we examined whether they activate the *Rorg* promoters in luciferase-based promoter reporter assays. We found that c-Rel and p65, but not p50 or RelB, significantly activated the *Rorg* promoters upon coexpression ([Fig. 6 A](#fig6){ref-type="fig"}; unpublished data). p50 and RelB failed to activate the *Rorg* promoters even when co-transfected together (unpublished data). This indicates that the Rel/NF-κB family of transcription factors may regulate *Rorg* gene expression in a member-specific manner.

![**c-Rel binds to and activates the *Rorg* promoter through two specific Rel sites.** (A) EL4 cells were transiently transfected with murine *Rorg* promoter luciferase construct together with an expression vector for full-length c-Rel, p65, p50, or RelB, or the empty vector as indicated. After 24 h, cells were treated with PMA and ionomycin for 5 h, and the luciferase activities measured. The promoter activity is presented as fold increase over cells transfected with empty vector. To normalize the transfection efficiency across samples, the *Renilla* luciferase expression vector pRLTK was included as an internal control. (B) Deletion mutants of the *Rorg* promoter were analyzed in the luciferase reporter assay with or without c-Rel co-transfection. Putative binding sites for c-Rel (Rel1 and Rel2) and NFAT are indicated. (C) WT and Rel or NFAT site-mutated *Rorg* promoter constructs were analyzed in the luciferase reporter assay with or without c-Rel co-transfection. The Rel1 site was mutated to TGGGACTCG (−201 to −193), the Rel2 site to CTGAAGTGC (−288 to −280), and the NFAT site to TTGTCAC (−96 to −90). The "X" indicates the mutated site. (D) Nuclear extracts were prepared from EL4 cells after stimulation for 6 h with PMA and ionomycin. Biotinylated *Rorg* Rel oligonucleotides or their mutants were absorbed by streptavidin-agarose beads, and then added to the nuclear extracts. The amount of c-Rel proteins in the precipitates were assessed by immunoblotting with anti--c-Rel. (E) Purified CD4^+^ T cells from 6-wk-old WT mice (*n* = 3) were cultured under Th17 differentiation conditions, as described in Materials and methods. After 17 h, cells were fixed, and ChIP was performed using anti--c-Rel or control IgG. \*, P \< 0.01. Data are representative of three (A--D) and two (E) independent experiments, respectively.](JEM_20110462_GS_Fig6){#fig6}

Rel binds to both *Rorg* and *Rorgt* promoters and controls their activities through specific Rel sites
-------------------------------------------------------------------------------------------------------

To identify the c-Rel--responsive region in the murine *Rorg* promoter, we performed deletional analysis of the promoter. We found that nucleotides −471 to −167 were required for the c-Rel activity ([Fig. 6 B](#fig6){ref-type="fig"}). A close examination of the nucleotide sequence in this region using the Transcription Element Search System (TESS) software revealed two putative Rel (or NF-κB) binding sites (Rel1, −201 to −193; Rel2, −288 to −280), and a putative NFAT-binding site (−96 to −90; Fig. S7). To determine whether these sites were required for c-Rel and p65 actions, we mutated them either individually or in combination. We found that both Rel1 and Rel2 sites, but not the putative NFAT site, were required for the c-Rel and p65 response ([Fig. 6 C](#fig6){ref-type="fig"}; unpublished data). Similarly, the *Rorgt* promoter contains a putative Rel site (Rel2, −268 to −260) and a putative Rel-NFAT--binding site (Rel1-NFAT, −166 to −156; Fig. S8). To identify the Rel-responsive site, we tested, in a luciferase reporter assay, the WT *Rorgt* promoter construct (−400 to +151) and its mutants ([Fig. 7 A](#fig7){ref-type="fig"}). We found that both Rel site mutations significantly reduced the *Rorgt* promoter activity, indicating that Rel regulates the *Rorgt* promoter through these sites.

![**c-Rel binds to and activates the *Rorgt* promoter through two Rel sites.** (A) WT and Rel site-mutated *Rorgt* promoter constructs and the empty vector were analyzed in a luciferase reporter assay with c-Rel co-transfection. The "X" indicates the mutated (Mu) Rel site. Data are representative of three independent experiments. (B) Nuclear extracts were prepared from EL4 cells after stimulation for 6 h with PMA and ionomycin. Biotinylated *Rorgt* Rel oligonucleotides or their mutants were absorbed by streptavidin-agarose beads, and then added to the nuclear extracts. The amount of c-Rel proteins in the precipitates were assessed by immunoblotting with anti--c-Rel. (C) Purified CD4^+^ T cells from 6-wk-old WT mice (*n* = 3) were cultured under Th17 differentiation condition as described in Materials and methods. After 17 h, cells were fixed, and ChIP was performed using anti--c-Rel or control IgG. Data are representative of two independent experiments. (D) Purified CD4^+^ T cells from 6-wk-old WT mice (*n* = 3) were cultured under Th17 differentiation conditions, as described in Materials and methods. After 17 h, cells were fixed, and ChIP was performed using anti--c-Rel. Data are representative of two independent experiments.](JEM_20110462_GS_Fig7){#fig7}

To directly test c-Rel binding to the identified Rel nucleotides of the *Rorg* and *Rorgt* promoter, we performed nucleotide pull-down analyses using both wild-type and mutant Rel nucleotides. We found that c-Rel readily bound to the nucleotides of all four Rel sites, but not their mutants ([Fig. 6 D](#fig6){ref-type="fig"} and [Fig. 7 B](#fig7){ref-type="fig"}).

To establish whether Rel binds to the *Rorg* and *Rorgt* promoter in Th17 cells, we performed ChIP analysis. The *Rorg* and *Rorgt* DNA--protein complexes were precipitated using specific antibodies to c-Rel and p65 at different time points of Th17 differentiation. The nature of the precipitated DNA was then defined by PCR using primers specific for *Rorg* and *Rorgt* promoter. We found that in resting naive T cells, the *Rorg* and *Rorgt* promoter was devoid of c-Rel and p65. 17 h after Th17 differentiation, c-Rel and p65 were readily detected on both the *Rorg* and *Rorgt* promoter ([Fig. 6 E](#fig6){ref-type="fig"} and [Fig. 7 C](#fig7){ref-type="fig"}). In addition to *Rorg* and *Rorgt*, c-Rel also bound to *Il2*, but not *Il17a*, during Th17 differentiation ([Fig. 7 D](#fig7){ref-type="fig"}). Re-ChIP analysis showed that c-Rel and p65 colocalized in the same complex ([Fig. 8, A and B](#fig8){ref-type="fig"}). p65 was also detected on the *Rorg* and *Rorgt* promoters in *Rel^−/−^* T cells during Th17 differentiation ([Fig. 8, C and D](#fig8){ref-type="fig"}). This result may explain why significant numbers of Th17 cells were generated in the absence of c-Rel,

![**Rel controls *Rorg* promoter activities in primary Th17 cells.** (A and B) Purified naive CD4^+^ T cells from WT (*n* = 3) mice were cultured under Th17 differentiation conditions, as described in Materials and methods. At indicated times, cells were fixed, and ChIP was performed using anti-p65 antibody. Re-ChIP was performed with anti--c-Rel using DNA precipitated by anti-p65. (C and D) Purified naive CD4^+^ T cells from 6-wk-old *Rel^−/−^* mice (*n* = 3) were cultured under Th17 differentiation conditions, as described in Materials and methods. After 17 h, cells were fixed, and ChIP was performed using anti-p65 antibody. (E--G) Naive CD4^+^ T cells from WT (E--G; *n* = 3) and *Rel^−/−^* mice (E; *n* = 3) were transiently transfected with WT (E--G) and Rel sites mutated (E) murine *Rorgt* promoter luciferase constructs using Amaxa Nucleofector reagent. An expression vector for full-length c-Rel was also used to co-transfect cells in E. Cells were cultured under Th17 differentiation condition for 24 h, and the luciferase activities measured. To normalize the transfection efficiency across samples, the *Renilla* luciferase expression vector pRLTK was included as an internal control. Error bars indicate the SEM. Data are representative of two independent experiments.](JEM_20110462_LW_Fig8){#fig8}

These results indicate that c-Rel is required for activating the *Rorg* and *Rorgt* promoter during Th17 differentiation. To directly test this possibility, we measured the *Rorgt* promoter activity in differentiating Th17 cells. We found that c-Rel deficiency significantly diminished, whereas c-Rel overexpression enhanced, the *Rorgt* promoter activity ([Fig. 8, E and F](#fig8){ref-type="fig"}). Additionally, we found that mutating the Rel binding sites of the *Rorgt* promoter significantly reduced its activity in primary Th17 cells ([Fig. 8 G](#fig8){ref-type="fig"}). These results establish that c-Rel not only can, but also does, activate the *Rorgt* promoter in Th17 cells.

c-Rel--deficient mice have diminished autoimmune Th17 responses
---------------------------------------------------------------

Th17 cells play crucial roles in the pathogenesis of autoimmune diseases. Because c-Rel--deficient T cells have a defect in Th17 differentiation, we asked whether Th17 responses to self-antigens were affected in c-Rel--deficient mice. As we reported, c-Rel--deficient mice were resistant to experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis ([@bib15]). To determine whether anti-self MOG (myelin oligodendrocyte glycoprotein) Th17 response was affected by the c-Rel deficiency, we immunized WT and c-Rel--deficient mice with a MOG peptide and examined the splenic T cell response to the self-peptide 2 wk later. We found that the anti-MOG Th17 response (as measured by IL-17 and IL-6 production) was significantly reduced in c-Rel--deficient mice as compared with their WT littermates ([Fig. 9 A](#fig9){ref-type="fig"}). To determine whether the in vivo effect of c-Rel on Th17 development was T cell intrinsic, we transferred WT and *Rel^−/−^* T cells into Rag1^−/−^ mice. Mice were then immunized with MOG peptide, and the splenic T cell responses to MOG were tested 2 wk later. The results showed that *Rel^−/−^* T cells produced significantly less IL-17 as compared with WT T cells ([Fig. 9 B](#fig9){ref-type="fig"}).

![**MOG-induced Th17 cytokine production by WT and *Rel^−/−^* splenocytes.** (A) WT (*Rel^+/+^*) and c-Rel--deficient (*Rel^−/−^*) C57BL/6 mice (*n* = 3) were immunized s.c. with 200 µg MOG38-50 peptide in 0.1 ml PBS emulsified in an equal volume of complete Freund's adjuvant containing 400 µg *Mycobacterium tuberculosis* H37RA. 14 d later, mice were sacrificed, and their splenocytes (5 × 10^6^/ml) were cultured with or without MOG38-50 peptide as indicated. Culture supernatants were collected 40 h later and tested for cytokines by ELISA ([@bib15]). (B) Purified T cells from WT (*Rel^+/+^*) and c-Rel--deficient (*Rel^−/−^*) C57BL/6 mice (*n* = 3) were transferred into *Rag1^−/−^* C57BL/6 mice via tail vein. Mice were treated and the splenic T cell responses to MOG examined as in A. Graphs show means ± SD of triplicate cultures. The differences between the two groups for all cultures with MOG are statistically significant (P \< 0.01). Data are representative of two experiments.](JEM_20110462_LW_Fig9){#fig9}

To determine if c-Rel deficiency affects other models of autoimmunity, we crossed our c-Rel--deficient B6 mice with a NOD mouse line that carried a transgenic diabetogenic TCR called BDC2.5 ([@bib13]). All WT progenies developed autoimmune diabetes upon challenging with cyclophosphamide (CY) even though they were of a mixed MHC background. Remarkably, none of the c-Rel--deficient mice developed diabetes as measured by blood glucose levels ([Fig. S9 A](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp9}). Consistent with these results, splenocytes from c-Rel--deficient mice produced significantly lower levels of IL-17A, IL-6, IL-2, and IFN-γ than WT cells upon stimulation with anti-CD3, with or without anti-CD28 (Fig. S9 B). Flow cytometric analysis revealed that in CD4^+^ T cells, both Th1 and Th17 cytokines were reduced as a result of the c-Rel deficiency (our unpublished data). Collectively, these results indicate that autoreactive Th17 responses are markedly diminished in c-Rel--deficient mice.

DISCUSSION
==========

How Th17 cells are generated remains enigmatic. Results reported here enable us to propose the following model ([Fig. 5](#fig5){ref-type="fig"}): APCs engage naive CD4^+^ T cells by TCR and CD28, in the presence of IL-1, IL-6, IL-23, and TGF-β; ligation of TCR, CD28, IL-1, and possibly IL-23 receptors leads to the activation of IKKβ, which phosphorylates IκBα (inhibitor of κBα), releasing c-Rel and p65. We propose that the freed c-Rel-p65 dimer migrates into the nucleus, binds to the *Rorg* and *Rorgt* promoters, and initiates Th17 differentiation, with the help of other factors such as NFAT and Stat. Thus, although the *Rorg* gene specifies Th17 lineage differentiation ([@bib18]), its own expression may not be controlled by lineage-specific factors. Similar principles also apply to other lineage-specifying genes, including *Foxp3*, which is controlled by c-Rel. In the latter case, c-Rel forms a multifactorial complex called the enhanceosome, together with other nonlineage-specific factors, to control the on and off states of the *Foxp3* gene. Although each factor in the enhanceosome is not unique, the complex as a whole is ([@bib29]). The enhanceosome operates as a "coincidence detector," turning on the *Foxp3* gene only when all the essential factors are present ([@bib29]). This concept explains how nonlineage-specific factors such as c-Rel control gene expression in a lineage-specific manner. Data presented in this work indicate that c-Rel and p65 may regulate *Rorg* gene expression in a similar manner, i.e., by forming an enhanceosome that in turn controls the on and off states of the *Rorg* gene. It is to be emphasized that the transcription factors (c-Rel and p65) we identified are the only known ones that bind to and activate *Rorg* promoters. Stat3 was recently shown to bind to the first intron of the *Rorg* gene, but not the promoter ([@bib10]). The nature of other *Rorg* promoter-binding transcription factors remains to be established.

Unlike RORγT, which is primarily expressed in developing thymocytes and Th17 cells, RORγ is expressed in a variety of cell types ([@bib14]; [@bib36]). However, naive T cells and Th0 cells do not express RORγ. Upon Th differentiation, RORγ is most significantly up-regulated in Th17 cells and is able to specify the Th17 phenotype. Therefore, at least in T cells, RORγ shares similar expression patterns and functions with RORγT. Because we found evidence for the presence of two active *Rorg* promoters and two types of 5′-capped RORγ mRNAs in Th17 cells, we propose that RORγT and RORγ are generated by differential usage of promoters. It has been recognized that more than one ROR member is involved in Th17 differentiation. Thus, Th17 cells were detected in *Rorg* knockout cultures that lack both RORγT and RORγ ([@bib18]), and Th17 responses could be completely blocked only in mice that lacked all three ROR members, i.e., RORγT, RORγ, and RORα ([@bib42]). Therefore, no single ROR protein deficiency may completely block Th17 differentiation. One of our novel findings is that RORγ, which is not expressed in naive T cells, is selectively induced in Th17 cells by c-Rel, and controls *Il17* gene expression. Although non--T cells can express RORγ, they may not express IL-17. This may be because of the fact that other T cell--associated factors, in addition to RORγT and RORγ, are required to activate the *Il17* gene.

The novel discovery from this work is that c-Rel regulates Th17 response via RORγ and RORγT. The possibility that c-Rel also directly activates the *Il17a* gene, in addition to activating *Rorg*, cannot be completely ruled out, but is not supported by our data. c-Rel failed to activate the *Il17a* promoter, and was not recruited to it during Th17 differentiation, as we demonstrated in this study. Additionally, we searched for putative Rel/NF-κB sites between nucleotides +1 and −4,000 of the mouse *Il17a* locus using the Transcription Element Search System software, and identified only one putative site at −3,629 bp. However, subsequent ChIP analysis using anti--c-Rel revealed no binding of c-Rel to this site during Th17 differentiation. Therefore, there is no evidence that c-Rel may also bind to the *Il17a* locus. Similarly, because we showed that Stat3 expression was not affected by c-Rel deficiency, c-Rel could not regulate Th17 differentiation through Stat3.

Differentiation of autoreactive CD4^+^ naive T cells into Th1 or Th17 effector cells is required for the development of autoimmune diseases. Nondifferentiated autoreactive naive T cells are not pathogenic. Our observation that c-Rel--deficient mice are resistant to EAE and T1D indicates that c-Rel--mediated T cell differentiation may play a critical role in the development of autoimmune diseases ([@bib15]; [@bib20]). However, because c-Rel regulates multiple gene expressions in both lymphocytes and myeloid cells ([@bib12]; [@bib5]), the disease resistance of c-Rel--deficient mice can be caused by the defect in either lymphoid or myeloid cells, or in both. Similarly, c-Rel may regulate Th cell differentiation in vivo through two distinct mechanisms: (1) c-Rel expressed by T cells may regulate their differentiation through an autonomous mechanism, e.g., by activating the promoters of Th17-specific genes such as *Rorg*; (2) c-Rel expressed by myeloid cells may regulate Th cell differentiation through a T cell nonautonomous mechanism, e.g., by regulating the expression of cytokines that drive Th17 differentiation. The autonomous theory is supported by the findings that (a) purified *Rel^−/−^* T cells exhibit a significant defect in Th17 cell differentiation; (b) c-Rel directly controls the RORγ and RORγT expression; and (c) IL-1, IL-23, and TGF-β, cytokines that promote Th17 cell differentiation, activate Rel/NF-κB ([@bib30]; [@bib7]; [@bib8]). Similarly, the nonautonomous theory is supported by the finding that the expression of IL-6 and IL-23, two cytokines that promote Th17 cell differentiation, is significantly reduced in c-Rel--deficient myeloid cells ([@bib20]; [@bib6]). Interestingly, using cDNA microarrays that cover the whole mouse genome, [@bib5] reported that the expression of ∼130 genes was reduced in c-Rel--deficient T cells as compared with WT cells treated with anti-CD3 and anti-CD28. These genes encode cytokines, chemokines, and cell surface molecules, as well as intracellular signal transducers and transcription factors. However, because *Rorg* expression is induced during Th17 differentiation, [@bib5] did not detect it in their cells, which were not of the Th17 type. Therefore, in addition to *Rorg,* other c-Rel target genes could also regulate Th17 responses in a cell autonomous manner. For example, both *Il2* and *Foxp3* are c-Rel target genes that are known to promote T reg cell differentiation and inhibit Th17 differentiation ([@bib17]; [@bib24]; [@bib29]; [@bib43]). Because c-Rel--deficient T cells produce less IL-2 than WT T cells, the effect of c-Rel deficiency on Th17 differentiation could be masked if anti--IL-2 was not included in the Th17 differentiation medium ([@bib23]; [@bib37]).

In summary, we have discovered that c-Rel and p65 play critical roles in Th17 immune responses. This finding may not only help advance our understanding of the Th17 differentiation program, but also aid in developing new drugs targeting Rel and RORγ for the treatment of inflammatory diseases.

MATERIALS AND METHODS
=====================

### Mice.

7--8-wk-old C57BL/6 (B6) mice that carry a *Rel* gene null mutation were generated as previously described, and were backcrossed to B6 mice for 12 generations before used in this study ([@bib23]; [@bib15]). p65-deficient fetal liver chimeric B6 mice were generated as previously described ([@bib26]). B6.NOD F1 mice were generated by crossing *Rel^−/−^* B6 and NOD BDC2.5 TCR transgenic mice ([@bib13]). The F1 mice were then crossed to generate *Rel^−/−^* and *Rel^+/+^* B6.NOD BDC2.5 TCR transgenic mice. All B6.NOD F2 mice used in this study were H-2 of b and g7 and express the BDC2.5 transgenic TCR as determined by flow cytometry. All mice were housed in the University of Pennsylvania animal care facilities under pathogen-free conditions, and all procedures were preapproved by the Institutional Animal Care and Use Committee.

### Induction and clinical evaluation of diabetes.

7--8-wk-old B6.NOD BDC2.5 TCR transgenic mice were injected i.p. with 200 mg/kg CY. Mice were tested every other day for blood glucose levels, and were considered diabetic if the glucose levels equaled or exceeded 250 mg/dl on two consecutive tests.

### Recombinant retroviruses.

The recombinant RORγT retrovirus was a gift from D.R. Littman (New York University, New York, NY; [@bib18]). A recombinant RORγ retrovirus was generated by inserting the murine RORγ cDNA with or without a Flag tag into the XhoI and EcoRI site of the MigR1 vector, and by transfecting 293T cells with the recombinant plasmid ([@bib27]; [@bib28]; [@bib32]). In the recombinant viral genome, the RORγ or RORγT cDNA lies directly 5′ of an internal ribosome entry site, which is followed by a cDNA encoding enhanced GFP (EGFP).

### T cell isolation and differentiation.

Naive CD4^+^CD25**^−^**CD44^low^CD62L^+^ splenic T cells were isolated by FACS after staining the cells with the specific antibodies. Total CD4^+^ T cells were isolated using an autoMACS cell sorter after staining splenocytes with anti-CD4. Cells were cultured with 2 µg/ml soluble anti-CD28 and 2 µg/ml plate-bound anti-CD3 under conditions that induce either Th0 (50 U/ml IL-2; also known as nondifferentiation medium), Th1 (50 U/ml IL-2, 10 ng/ml IL-12, and 1 µg/ml anti--IL-4), Th2 (50 U/ml IL-2, 10 ng/ml IL-4, 1 µg/ml anti--IL-12, and 1 µg/ml anti--IFN-γ), or Th17 (2 µg/ml anti--IL-2, 1 µg/ml anti--IL-4, 1 µg/ml anti--IFN-γ, 20 ng/ml IL-6, and 5 ng/ml TGF-β1) cells. 3 d later, cells were washed and restimulated with 50 ng/ml PMA and 1 µM ionomycin in the presence of GolgiStop (1:1,500 dilution; BD) for 4--5 h, stained intracellularly with anti--IL-17A and anti--IFN-γ (eBioscience), and examined by flow cytometry.

### ChIP assay.

ChIP was performed using the ChIP assay kit, per the manufacturer's instructions (Millipore). In brief, cells were fixed with 1% formaldehyde at room temperature for 10 min and lysed in lysis buffer. DNA was then fragmented by sonication. After preclearance for 1 h at 4°C with salmon sperm DNA-saturated protein A-agarose, chromatin solutions were immunoprecipitated overnight at 4°C using 1 µg of rabbit antibodies to c-Rel, p65, RNA Polymerase II (Santa Cruz Biotechnology, Inc.), or control rabbit IgG. For the RORγ ChIP, anti-Flag, control mouse IgG, and the salmon sperm DNA-saturated protein G-agarose were used. Input and immunoprecipitated chromatins were incubated for 4 h at 65°C to reverse cross-links. After proteinase K digestion, DNA was extracted with phenol/chloroform and precipitated with ethanol. ChIP DNA was then analyzed by real-time PCR (the sequences of the primers are listed in the [Supplemental materials and methods](http://www.jem.org/cgi/content/full/jem.20110462/DC1){#supp10}).

### RT-PCR.

Total RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's instructions. Reverse transcription was performed using oligo dT primers. Quantitative real-time PCR was performed in the Applied Biosystems 7500 system using Power SYBR Green PCR Master Mix (Applied Biosystems). Relative levels of gene expression were determined using *GAPDH* as the control (the sequences of the primers are listed in the Supplemental materials and methods).

### ELISA.

Antibodies used in ELISA were purchased from BD, including purified and biotinylated rat anti--mouse IL-2, IL-6, IFN-γ, and IL-17A. Quantitative ELISA was performed according to the manufacturer's recommendations using paired mAbs specific for corresponding cytokines.

### Western blot.

Total cell lysates were prepared by treating cells with the RIPA buffer, which contains 150 mM NaCl, 10 mM Tris, pH 7.4, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 100 µM Na~3~VO~4~, 5 mM EDTA, 1 mM PMSF, and protease inhibitors. Proteins (20 µg per lane) were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and blotted with specific antibodies.

### 5′-RACE.

Purified CD4^+^ T cells from 6-wk-old WT mice were cultured under Th17 differentiation condition for 17 h. Total RNA was extracted (TRIzol) and treated with RNase-free DNase I (Promega). 5′-RACE was performed with a RNA ligase-mediated RACE (RLM-RACE) kit (Invitrogen). PCR products of 5′ end of mRNA were purified by agarose gel electrophoresis, cloned, and sequenced.

### Nucleotide pull-down assay.

EL4 T cells were stimulated with 50 ng/ml PMA (Sigma-Aldrich) and 1 µM/ml ionomycin (Sigma-Aldrich) for 6 h at 37°C. The cells were resuspended in lysis buffer (20 mM Hepes, 420 mM NaCl, 1.5 mM MgCl~2~, 0.2 mM EDTA, 1 mM DTT, and 0.1% Nonidet P-40) with protease inhibitors, and incubated on ice for 15 min. Insoluble materials were removed by centrifugation. 100 µg lysate protein was diluted with dilution buffer (which is the same as the aforementioned lysis buffer, but without NaCl) and incubated with 10 µg of poly(deoxyinosinic-deoxycytidylic acid) (Roche) and 50 µl of streptavidin-agarose beads (Sigma-Aldrich) carrying biotinylated oligonucleotides (as described at teh end of this section) for 3 h at 4°C. The beads were washed twice with dilution buffer, resuspended in 50 µl 2X SDS sample loading buffer (Bio-Rad Laboratories), and heated to 95°C for 10 min. The eluants were resolved by SDS-PAGE. c-Rel was detected by immunoblotting with specific antibodies against c-Rel (Santa Cruz Biotechnology, Inc.). The oligonucleotides containing either the WT or mutated Rel binding sites used in this study are as follows: RORγ-Rel1-201, 5′-­GGGTTATCATG­TGGGATTCCAA­AAAACAAAC-3′; RORγ-Rel1-201 mutant, 5′-­GGGTTATCATG­TGGGACTCGAA­AAAACAAAC-3′; RORγ-Rel2-288, 5′-GAATTGCCCT­TGTGAATTCCT­GGCAAGTCTT-3′; RORγ-Rel2-288 mutant, 5′-­GAATTGCCCTT­CTGAAGTGCTG­GCAAGTCTT-3′; RORγt-Rel1-166, 5′-­TAGCTGTGGTT­TTGGAATTTTC­CAACGCCCCCT-3′; RORγt-Rel1-166 mutant, 5′-­TAGCTGTGGTT­TTAACATTGGA­TAACGCCCCCT-3′; RORγt-Rel2-268, 5′-GTACTCAGGA­GAGGGGATTTC­GAGCCTGGCCTC-3′; RORγt-Rel2-268 mutant, 5′-­GTACTCAGGAG­AGACGATCCCG­AGCCTGGCCTC-3′.

### Promoter luciferase assay.

The following DNA fragments were cloned into pGL3 luciferase reporter plasmid: the *Rorg* promoter (0.87 kb) and their mutants, the *Rorgt* promoter (0.55 kb) and their mutants, the *Il17a* promoter (1.1 kb) with or without the *Il17a* CNS2 (0.9 kb), and the *Rora4* promoter (1.1 kb). Site-directed mutagenesis of Rel and NFAT binding sites was performed using the QuikChange kit (Stratagene), according to manufacturer's instructions. DNA sequencing was used to confirm the mutated nucleotides. To test the promoter activity, T cells were transfected with the aforementioned reporter constructs together with expression plasmids carrying murine c-Rel, p65, p50, RelB, RORγ, or RORγT cDNA using Lipofectamine LTX (Invitrogen) or Amaxa Nucleofector reagents (Lonza). After 24 h, cells were treated with or without 50 ng/ml PMA and 1 µM ionomycin for 4--5 h, and the luciferase activities of whole-cell lysates were analyzed using the dual-luciferase reporter assay system (Promega). Co-transfection with the *Renilla*-luciferase expression vector pRL-TK (Promega) was performed in all reporter assays. For all samples, the assays were repeated at least three times and the data were normalized for transfection efficiency by dividing firefly luciferase activity by that of the *Renilla* luciferase.

### Statistical analyses.

Glucose concentrations, real-time PCR results, and cytokine concentrations were analyzed by Student's *t* test. Disease incidence was analyzed by Mann-Whitney *U* test.

### Online supplemental material.

Fig. S1 shows reduced Th17 response of c-Rel--deficient T cells. Fig. S2 shows proliferation and phenotypes of *Rel^−/−^* T cells. Fig. S3 shows defective Th17 differentiation of *p65^−/−^* T cells. Fig. S4 shows regulation of the IL-17 gene expression. Fig. S5 shows that enforced expression of RORγ and RORγT did not rescue the proliferation defect of *Rel^−/−^* CD4 T cells. Fig. S6 shows the role of RORγ in Th cell differentiation. Fig. S7 shows sequence alignment of the human, mouse, and rat *Rorg* promoter regions. Fig. S8 shows sequence alignment of the human, mouse, and rat *Rorgt* promoter regions. Fig. S9 shows that c-Rel--deficient mice are completely resistant to type 1 diabetes. Supplemental materials and methods lists nucleotide sequences. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20110462/DC1>.
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